See more : LS Networks Corporation Limited (000680.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Antares Pharma, Inc. (ATRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Antares Pharma, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Banco Comercial Português, S.A. (BCP.LS) Income Statement Analysis – Financial Results
- DeepSpatial Inc. (DSAI.CN) Income Statement Analysis – Financial Results
- Mayr-Melnhof Karton AG (MMK.VI) Income Statement Analysis – Financial Results
- Keen Vision Acquisition Corporation Ordinary Shares (KVAC) Income Statement Analysis – Financial Results
- Discovery Minerals Ltd. (DSCR) Income Statement Analysis – Financial Results
Antares Pharma, Inc. (ATRS)
About Antares Pharma, Inc.
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 183.98M | 149.60M | 123.86M | 63.55M | 54.52M | 52.22M | 45.66M | 26.50M | 20.62M | 22.58M | 16.46M | 12.82M | 8.31M | 5.66M | 7.86M | 4.27M | 2.22M | 2.75M | 3.79M | 4.00M | 3.50M | 1.99M | 3.48M | 2.75M | 3.72M | 3.69M |
| Cost of Revenue | 68.28M | 63.10M | 50.48M | 31.07M | 27.47M | 28.82M | 19.46M | 11.24M | 9.20M | 9.52M | 6.80M | 4.27M | 4.14M | 2.02M | 3.44M | 1.56M | 1.14M | 1.37M | 2.01M | 2.57M | 1.86M | 1.65M | 1.79M | 1.85M | 1.22M | 1.14M |
| Gross Profit | 115.70M | 86.50M | 73.39M | 32.49M | 27.05M | 23.41M | 26.20M | 15.26M | 11.42M | 13.06M | 9.66M | 8.55M | 4.17M | 3.64M | 4.41M | 2.71M | 1.09M | 1.37M | 1.78M | 1.42M | 1.64M | 346.65K | 1.70M | 898.84K | 2.50M | 2.56M |
| Gross Profit Ratio | 62.89% | 57.82% | 59.25% | 51.12% | 49.62% | 44.82% | 57.38% | 57.60% | 55.39% | 57.83% | 58.70% | 66.66% | 50.19% | 64.32% | 56.19% | 63.55% | 48.90% | 50.02% | 46.98% | 35.60% | 46.75% | 17.39% | 48.72% | 32.67% | 67.15% | 69.22% |
| Research & Development | 14.50M | 10.12M | 10.62M | 12.33M | 13.15M | 21.13M | 19.73M | 18.64M | 15.26M | 14.92M | 6.70M | 8.80M | 7.90M | 7.87M | 5.36M | 3.78M | 3.41M | 3.55M | 3.49M | 3.65M | 3.56M | 1.22M | 2.42M | 3.52M | 2.57M | 2.58M |
| General & Administrative | 0.00 | 62.76M | 61.77M | 36.76M | 30.35M | 26.39M | 26.93M | 31.74M | 8.29M | 7.20M | 5.85M | 4.73M | 4.91M | 6.35M | 7.70M | 7.21M | 6.27M | 6.20M | 6.92M | 6.03M | 6.70M | 1.97M | 1.83M | 2.43M | 3.36M | 1.40M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.71M | 2.38M | 1.55M | 1.04M | 1.05M | 1.62M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 627.91K | 1.06M | 1.00M | 0.00 | 1.02M |
| SG&A | 73.86M | 62.76M | 61.77M | 36.76M | 30.35M | 26.39M | 26.93M | 31.74M | 17.01M | 9.59M | 7.40M | 5.77M | 5.96M | 7.97M | 7.70M | 7.21M | 6.27M | 6.20M | 6.92M | 6.03M | 6.70M | 2.60M | 2.89M | 3.43M | 3.36M | 2.42M |
| Other Expenses | 68.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00M | 0.00 | 1.39M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 156.64M | 72.88M | 72.40M | 49.09M | 43.50M | 47.52M | 46.66M | 50.38M | 32.27M | 24.51M | 14.10M | 14.57M | 13.86M | 15.84M | 13.06M | 10.99M | 9.68M | 9.75M | 10.41M | 11.68M | 10.26M | 5.22M | 5.31M | 6.94M | 5.94M | 5.00M |
| Cost & Expenses | 224.92M | 135.98M | 122.87M | 80.16M | 70.97M | 76.34M | 66.12M | 61.61M | 41.47M | 34.03M | 20.90M | 18.85M | 18.00M | 17.86M | 16.50M | 12.55M | 10.81M | 11.12M | 12.42M | 14.26M | 12.12M | 6.87M | 7.09M | 8.80M | 7.16M | 6.14M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 79.78K | 60.47K | 76.66K | 111.58K | 63.20K | 55.59K | 30.68K | 27.27K | 553.06K | 0.00 | 353.24K | 128.83K | 0.00 | 16.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 3.79M | 3.55M | 2.68M | 1.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 887.00 | 4.46K | 633.46K | 1.02M | 0.00 | 3.13K | 576.00 | 0.00 | 920.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.90M | 2.63M | 2.56M | 2.72M | 2.10M | 1.86M | 1.57M | 1.22M | 558.28K | 231.03K | 168.17K | 188.75K | 226.38K | 283.32K | 2.78M | 493.62K | 513.26K | 776.33K | 894.30K | 2.05M | 560.63K | 413.70K | 461.34K | 596.73K | 326.07K | 178.53K |
| EBITDA | 66.17M | 16.34M | 4.08M | -1.12M | -13.22M | -22.38M | -18.91M | -33.90M | -20.25M | -11.20M | -4.22M | -5.90M | -9.43M | -11.39M | -5.80M | -7.60M | -7.98M | -7.57M | -31.00M | -9.55M | -8.94M | -4.47M | -3.24M | -5.17M | -2.65M | -2.06M |
| EBITDA Ratio | 35.97% | 10.92% | 3.29% | -1.76% | -24.24% | -42.85% | -41.43% | -127.93% | -98.21% | -49.60% | -25.63% | -46.01% | -113.47% | -201.13% | -73.83% | -178.13% | -358.88% | -275.76% | -818.72% | -239.11% | -255.43% | -224.17% | -93.11% | -188.04% | -71.18% | -55.80% |
| Operating Income | 62.27M | 13.62M | 992.00K | -4.10M | -16.45M | -24.12M | -20.46M | -35.11M | -20.85M | -11.45M | -4.44M | -6.03M | -9.69M | -12.20M | -8.65M | -8.28M | -8.59M | -8.37M | -8.63M | -10.26M | -9.57M | -4.87M | -3.61M | -6.05M | -3.44M | -2.45M |
| Operating Income Ratio | 33.85% | 9.10% | 0.80% | -6.45% | -30.18% | -46.18% | -44.82% | -132.49% | -101.12% | -50.73% | -26.96% | -47.01% | -116.64% | -215.48% | -110.04% | -193.91% | -386.07% | -304.98% | -228.00% | -256.82% | -273.56% | -244.42% | -103.71% | -219.78% | -92.55% | -66.25% |
| Total Other Income/Expenses | 0.00 | -3.70M | -3.02M | -2.41M | -292.00K | -122.34K | -21.87K | -13.42K | 43.54K | 24.05K | -5.84K | -90.95K | 9.08K | -23.87K | -33.03K | -173.12K | -37.04K | 6.31K | -23.28M | -1.35M | 73.46K | -9.97K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 62.27M | 9.92M | -2.03M | -6.52M | -16.74M | -24.24M | -20.48M | -35.13M | -20.81M | -11.43M | -4.44M | -6.12M | -9.68M | -12.22M | -8.68M | -8.45M | -8.63M | -8.37M | -31.91M | -11.61M | -9.50M | -4.88M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 33.85% | 6.63% | -1.64% | -10.25% | -30.71% | -46.41% | -44.86% | -132.55% | -100.91% | -50.62% | -26.99% | -47.72% | -116.53% | -215.91% | -110.46% | -197.97% | -387.74% | -304.75% | -842.77% | -290.50% | -271.46% | -244.92% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 15.98M | -46.28M | 530.00K | 261.00K | 1.13M | 100.00K | 175.00K | 25.00K | -300.00K | 24.05K | -4.95K | -86.49K | 642.54K | 997.81K | -33.03K | -169.99K | -36.46K | 6.31K | -22.36M | 1.10K | 2.03K | -9.97K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 46.29M | 56.20M | -2.03M | -6.52M | -16.74M | -24.34M | -20.66M | -35.15M | -20.51M | -11.43M | -4.39M | -6.09M | -10.29M | -12.69M | -8.58M | -8.10M | -8.50M | -8.35M | -32.82M | -11.61M | -9.50M | -4.88M | -3.70M | -5.77M | -2.97M | -2.24M |
| Net Income Ratio | 25.16% | 37.57% | -1.64% | -10.25% | -30.71% | -46.61% | -45.25% | -132.64% | -99.46% | -50.62% | -26.66% | -47.52% | -123.82% | -224.18% | -109.19% | -189.76% | -381.97% | -304.03% | -866.63% | -290.53% | -271.52% | -244.92% | -106.36% | -209.73% | -79.95% | -60.64% |
| EPS | 0.27 | 0.33 | -0.01 | -0.04 | -0.11 | -0.16 | -0.14 | -0.27 | -0.16 | -0.10 | -0.05 | -0.07 | -0.14 | -0.19 | -0.14 | -0.16 | -0.20 | -0.23 | -2.17 | -1.21 | -1.12 | -3.42 | -2.60 | -4.06 | -2.12 | -1.93 |
| EPS Diluted | 0.27 | 0.33 | -0.01 | -0.04 | -0.11 | -0.16 | -0.14 | -0.27 | -0.16 | -0.10 | -0.05 | -0.07 | -0.14 | -0.19 | -0.14 | -0.16 | -0.20 | -0.23 | -2.17 | -1.21 | -1.12 | -3.42 | -2.60 | -4.06 | -2.12 | -1.93 |
| Weighted Avg Shares Out | 170.16M | 170.16M | 202.70M | 162.88M | 156.05M | 154.99M | 146.59M | 130.55M | 126.90M | 110.19M | 96.99M | 83.17M | 73.49M | 67.23M | 59.60M | 51.58M | 41.46M | 36.35M | 15.09M | 9.62M | 8.49M | 1.43M | 1.42M | 1.42M | 1.40M | 1.16M |
| Weighted Avg Shares Out (Dil) | 170.16M | 170.16M | 202.70M | 162.88M | 156.05M | 154.99M | 146.59M | 130.55M | 126.90M | 110.19M | 96.99M | 83.17M | 73.49M | 67.23M | 59.60M | 51.58M | 41.46M | 36.35M | 15.09M | 9.62M | 8.49M | 1.43M | 1.42M | 1.42M | 1.40M | 1.16M |
Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference
Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results
A Look At Recent Moves By Antares Pharma
FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity
Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q3 2021 Results - Earnings Call Transcript
Antares Pharma (ATRS) Reports Next Week: What to Expect
Antares Pharma to Report Third Quarter 2021 Financial and Operating Results
Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
Antares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Got $1,000? These 2 Bargain-Bin Biopharma Stocks Might Be Worth Buying
Source: https://incomestatements.info
Category: Stock Reports